grant
Yale SPORE in Skin Cancer
NIHUS FederalResearch GrantFY2025Adaptive Immune SystemAddressAgonistAnimal ModelAnimal Models and Related StudiesAntibodiesAntitumor ResponseAssayAwardBackBioassayBioinformatics coreBioinformatics research coreBioinformatics resource coreBiological AssayBiological MarkersBiologyBiostatistics CoreBody TissuesBp50CD40CDW40CancersCell BodyCell Culture TechniquesCellsCheckpoint inhibitorClinicClinicalClinical TreatmentClinical TrialsCollaborationsCytotoxic cellDataDevelopmentDiseaseDisorderDorsumESETEarly-Stage Clinical TrialsEffector CellEnvironmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEyeEyeballFosteringFundingFutureGeneticGoalsHistone-Lysine MethyltransferaseHistone-Lysine N-MethyltransferaseHumanIFN-GammaIFN-Gamma-Inducing Factor GeneIFN-gIFN-gamma-Inducing FactorIFN-γIFNGIFNγIGIFIGIF GeneIL-1 GammaIL-1 Gamma GeneIL-18IL-18 GeneIL-18 receptorIL-1gIL-1g GeneIL18IL18 ProteinIL18 geneIL1F4IL1F4 GeneImmune EvasionImmune InterferonImmune Modulation TherapyImmune checkpoint inhibitorImmune mediated therapyImmunobiologyImmunocompetentImmunologically Directed TherapyImmunooncologyImmunophysiologyImmunotherapyIncidenceInnate Immune SystemInnate ImmunityInstitutionInterdisciplinary ResearchInterdisciplinary StudyInterferon GammaInterferon Type IIInterferon-Gamma-Inducing Factor GeneInterferon-gamma-Inducing FactorInterleukin 18 (Interferon-Gamma-Inducing Factor)Interleukin 18 (Interferon-Gamma-Inducing Factor) GeneInterleukin 18 ProproteinInterleukin 18 Proprotein GeneInterleukin-1 GammaInterleukin-1 Gamma GeneInterleukin-18Interleukin-18 PrecursorInterleukin-18 Precursor GeneInvestigatorsJARID1BJumonji, AT-Rich Interactive Domain 1BK lymphocyteKDM5BKDM5B geneKG1TKIAA0067LeannessLysine-Specific Demethylase 5BMGC12320MGC12320 GeneMGC9013MacrophageMalignant MelanomaMalignant NeoplasmsMalignant Skin NeoplasmMalignant TumorMelanomaMelanoma CellMelanoma MetastasisMelanoma patientMessenger RNAMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic MelanomaMetastatic NeoplasmMetastatic TumorMethodsMiceMice MammalsModelingModern ManMorbidityMorbidity - disease rateMultidisciplinary CollaborationMultidisciplinary ResearchMurineMusMφNK CellsNative ImmunityNatural ImmunityNatural Killer CellsNeoplasm MetastasisNon-Specific ImmunityNonspecific ImmunityOutcomePD-1 antibodyPD-1 inhibitorsPD-1/PD-L1PD-1/PDL1PD-L1 blockadePD1 antibodyPD1 inhibitorsPD1-PD-L1PD1/PD-L1PD1/PDL1PDL1 blockadePLU-1 ProteinPLU1PUT1Pathway interactionsPatient SelectionPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhase 1 Clinical TrialsPhase I Clinical TrialsPre-Clinical ModelPreclinical ModelsProductivityProgram DevelopmentProtein Lysine MethyltransferaseProtein Methylase IIIProtein Methyltransferase IIIProteinsPutative DNA/Chromatin-Binding Motif 1RBBP2H1ARegimenResearchResearch PersonnelResearch ResourcesResearchersResistanceResourcesRetinoblastoma-Binding Protein 2 Homolog 1ARetinoblastoma-Binding Protein 2, Homolog 1ARetroelementsSETDB1SETDB1 geneSYS-TXSamplingScienceSecondary NeoplasmSecondary TumorSeriesSignal RepressionSiteSkin CancerStem Cell likeSystemic TherapyT cell infiltrationT-CellsT-LymphocyteTNFRSF5TNFRSF5 geneTechnologyTeff cellThinnessTissuesToxic effectToxicitiesTranslatingTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor CellTumor Necrosis Factor Receptor Superfamily Member 5 GeneVariantVariationWorkYale Cancer CenteraCTLA-4aCTLA-4 antibodiesaCTLA4aPD-1aPD1acquired immune systemadvanced diseaseadvanced illnessanti programmed cell death 1anti programmed cell death protein 1 inhibitoranti-CTLA-4anti-CTLA-4 antibodiesanti-CTLA4anti-CTLA4 antibodiesanti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 inhibitorsanti-PD-1 monoclonal antibodiesanti-PD-L1 blockadeanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 inhibitorsanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor responseantiPD-1bench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practicebio-markersbiologic markerbiomarkerbiomarker developmentcancer metastasiscareercell culturecell culturesclinical applicabilityclinical applicationclinical interventionclinical therapycohortcytokinecytokine based immunotherapycytokine based therapycytokine immunotherapycytokine therapycytokine treatmentderepressiondesigndesigningdevelopmentaldigital pathologyeffector T cellepigeneticallyhistone demethylaseimmune check point inhibitorimmune competentimmune evasiveimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmune-oncologyimmuno oncologyimmuno therapyimmunology oncologyimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimprovedimproved outcomeinhibitorinnovateinnovationinnovativeinterleukin-18 receptorlFN-GammamRNAmalignancymalignant skin tumormedical collegemedical schoolsmodel of animalmortalitymouse modelmurine modelneo-antigenneo-epitopesneoantigensneoepitopesneoplasm/cancerneoplastic cellnew approachesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew technologynew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generationnext generation therapeuticsnovelnovel approachesnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel technologiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoncoimmunologyoptimal therapiesoptimal treatmentsp50pathwaypatient oriented outcomespatients suffering from melanomapatients with melanomaphase I protocolpredict responsivenesspredicting responsepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreservationpreventpreventingprogenitor capacityprogenitor cell likeprogenitor-likeprogramsresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponseschool of medicinestem cell characteristicsstem-likestemnesstherapeutic immunomodulationtherapeutic immunoregulationtherapeutic resistancetherapy resistantthymus derived lymphocytetranslational cancer researchtranslational investigatortranslational researchertranslational scientisttreatment resistancetrial regimentrial treatmenttumortumor cell metastasisα-CTLA-4α-CTLA4αCTLA-4αCTLA4αPD-1αPD1
Description preview
OVERALL: PROJECT SUMMARY
The Yale SPORE in Skin Cancer (YSPORE), now in its third funding cycle, involves a broad range of projects
and investigators with diverse expertise, whose goal is to decrease mortality from melanoma by developing novel
drugs and regimens to treat patients once it metastasizes and develop predictive biomarkers to select…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click